The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Takeda Pharmaceutical's new drug application (NDA) of Adcetris (brentuximab vedotin) 50mg intended to treat patients with CD30 positive relapsed or refractory hodgkin ...
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited (Takeda), has received approval of ADCETRIS (brentuximab vedotin) from the Japanese Ministry of Health, Labour and Welfare ...
US-based privately-held therapeutic antibody firm AnaptysBio has commenced an antibody development program with Momenta Pharmaceuticals, focused on the development of new antibodies against a therapeutically relevant target. Both the ...
Sutro Biopharma has received $26m in a Series D financing, which will be used for the expansion of its proprietary immuno-oncology product pipeline. The company is currently using its cell-free protein synthesis technology to develop new ...
AstraZeneca's global biologics research and development division MedImmune will acquire Spirogen, a biotech firm focused on antibody-drug conjugate technology for use in oncology. Spirogen's complete shares will be purchased by MedImmune ...
Tags: biologics research, AstraZeneca
US-based biotechnology firm that develops novel anticancer therapeutics using antibody-drug conjugate (ADC) technology, ImmunoGen (IMGN) has signed a licensing agreement with Novartis, pursuant to which, Novartis has the exclusive right to ...
Tags: Immunogen, Novartis, ADC Technology
Therapeutic antibodies developer AnaptysBio has expanded its proprietary immunotherapy antibody portfolio to add multiple new combination therapies. The company developed a proprietary anti-PD-1 antibody, called ANB011, with key ...
Tags: AnaptysBio, Antibody Portfolio
US-based Ambrx and China-based Zhejiang Medicine have collaborated to develop and commercialize ARX788, an antibody drug conjugate (ADC) targeting Her2-positive breast cancer. As per the deal, both the companies will advance the product ...
Genmab and ADC Therapeutics have partnered to co-develop a new antibody-drug conjugate (ADC) product conjugate to treat multiple cancer indications. The collaboration will integrate Genmab's high-affinity fully human antibody targeting ...
Tags: Genmab, ADC Partner
Lonza has received a contract from Intellect Neurosciences to develop and manufacture the antibody drug conjugate, Conjumab-A. Under the contract, Lonza will supply the preclinical study material for the drug optimization and drug ...
Tags: Lonza, antibody drug, Neurosciences, antibody drug conjugate
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended conditional approval for Takeda Pharmaceuticals and Millennium adcetris (brentuximab vedotin) in Europe. If the CHMP ...
Tags: CHMP, refractory CD30 positive Hodgkin lymphoma, sALCL
Takeda Pharmaceutical Company and Millennium: The Takeda Oncology Company have won European conditional marketing authorization for Adcetris (brentuximab vedotin). Adcetris is indicated for use in adult patients with relapsed or ...
Tags: adcetris, antibody-drug conjugate, Brentuximab vedotin, sALCL
Sweden based Karolinska Institutet and Immunomedics scientists have collaborated to design and test new class of drugs that destroy the AIDS virus, HIV (Human Immunodeficiency Virus), which may also help in eliminating the virus completely. ...
Tags: Immunomedics, anti-HIV agents, virus
Antibody-drug conjugate (ADC) company, Mersana Therapeutics and Adimab have initiated a joint effort to offer integrated antibody discovery and ADC technologies. The partnership will provide pharmaceutical companies an access to Adimab's ...
Tags: Adimab, Mersana, integrated antibody discovery, ADC technologies